SCHEMBL6904419

SCHEMBL6904419

CCOc1ccc(/C(C)=N\OCCOc2ccc(CC3SC(=O)NC3=O)cc2)cn1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 14/20 0.72
CYP3A4 P08684 2/20 0.51
RXRA P19793 1/20 0.51
MPC2 O95563 2/20 0.48
CYP2C8 P10632 2/20 0.48
CYP2C9 P11712 2/20 0.48
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 1/20 0.47
TP53 P04637 1/20 0.47
CYP1A2 P05177 1/20 0.47
MAPT P10636 1/20 0.47
HPGD P15428 1/20 0.47
ALOX15 P16050 1/20 0.47
TSHR P16473 1/20 0.47
KMT2A Q03164 1/20 0.47
HSD17B10 Q99714 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
FFAR1 O14842 3/20 0.46
PPARA Q07869 1/20 0.45
ESR1 P03372 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6904420 1.00 PPARG (0.72) PPARGCYP3A4RXRAMPC2CYP2C8
SCHEMBL6898686 0.92 PPARG (0.73) PPARGCYP3A4RXRAMPC2CYP2C8
SCHEMBL6898681 0.92 PPARG (0.73) PPARGCYP3A4RXRAMPC2CYP2C8
SCHEMBL8308613 0.90 PPARG (0.76) PPARGCYP3A4RXRAFFAR1PPARA
SCHEMBL8308611 0.90 PPARG (0.76) PPARGCYP3A4RXRAFFAR1PPARA
SCHEMBL8306378 0.90 PPARG (0.69) PPARGCYP3A4RXRAMPC2CYP2C8
SCHEMBL8306376 0.90 PPARG (0.69) PPARGCYP3A4RXRAMPC2CYP2C8
SCHEMBL6902220 0.89 PPARG (0.70) PPARGCYP3A4RXRAMPC2CYP2C8
SCHEMBL6902217 0.89 PPARG (0.70) PPARGCYP3A4RXRAMPC2CYP2C8
SCHEMBL8305416 0.88 PPARG (0.76) PPARGCYP3A4RXRAMPC2CYP2C8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0919232-B1 Composition for use in the treatment and prevention of hyperuricemia SANKYO CO (JP) 2004-10-06 EP claimed
US-6353009-B1 TREATMENT OF GOUT WITH ANTIINFLAMMATORY AGENTS SANKYO COMPANY, LIMITED (JP) 2002-03-05 US claimed
EP-0919232-A1 Composition for use in the treatment and prevention of hyperuricemia Sankyo Company Limited (JP) 1999-06-02 EP claimed
EP-0708098-B1 Oxime derivatives, their preparation and their therapeutic use SANKYO CO (JP) 1999-03-03 EP claimed
EP-0708098-A1 Oxime derivatives, their preparation and their therapeutic use SANKYO COMPANY LIMITED (JP) 1996-04-24 EP claimed
EP-0919232-B1 Composition for use in the treatment and prevention of hyperuricemia SANKYO CO (JP) 2004-10-06 EP disclosed
US-6353009-B1 TREATMENT OF GOUT WITH ANTIINFLAMMATORY AGENTS SANKYO COMPANY, LIMITED (JP) 2002-03-05 US disclosed
US-6150371-A WITH THE EXCEPTION OF TYPE I DIABETES; INHIBITS INVASION OF ORGAN TISSUE BY CYTOTOXIC LYMPHOCYTES; ADMINISTERING TO A MAMMAL AN ANTIAUTOIMMUNE DISEASE AGENT BEING AN INSULIN RESISTANCE REDUCING AGENT, ANTIDIABETIC, E.G., TROGLITAZONE SANKYO COMPANY, LIMITED (JP) 2000-11-21 US disclosed
EP-0953355-A1 REMEDY FOR AUTOIMMUNE DISEASES Sankyo Company, Limited (JP) 1999-11-03 EP disclosed
US-5972959-A Oxime derivatives, their preparation and their therapeutic use SANKYO COMPANY, LIMITED (JP) 1999-10-26 US disclosed
EP-0919232-A1 Composition for use in the treatment and prevention of hyperuricemia Sankyo Company Limited (JP) 1999-06-02 EP disclosed
EP-0708098-B1 Oxime derivatives, their preparation and their therapeutic use SANKYO CO (JP) 1999-03-03 EP disclosed
EP-0708098-A1 Oxime derivatives, their preparation and their therapeutic use SANKYO COMPANY LIMITED (JP) 1996-04-24 EP disclosed